KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases

Laurence H Beck Jr; Isabelle Ayoub; Dawn Caster; Michael J Choi; Jason Cobb; Duvuru Geetha; Michelle N Rheault; Shikha Wadhwani; Timothy Yau; William L Whittier

doi:10.1053/j.ajkd.2023.02.003

KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases

Am J Kidney Dis. 2023 Aug;82(2):121-175. doi: 10.1053/j.ajkd.2023.02.003. Epub 2023 Jun 21.

Authors

Affiliations

¹ Division of Nephrology, Department of Medicine, Chobanian & Avedisian School of Medicine, Boston University, Boston, Massachusetts.
² Department of Medicine, Division of Nephrology, Wexner Medical, The Ohio State University, Columbus, Ohio.
³ Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
⁴ MedStar Georgetown University Hospital, Washington, DC.
⁵ Division of Renal Medicine, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
⁶ Division of Nephrology, Johns Hopkins University, Baltimore, Maryland.
⁷ Department of Pediatrics, Division of Pediatric Nephrology, Masonic Children's Hospital, University of Minnesota, Minneapolis, Minnesota.
⁸ Division of Nephrology and Hypertension, Northwestern University, Chicago, Illinois.
⁹ Division of Nephrology, Department of Medicine, School of Medicine, Washington University, St. Louis, Missouri.
¹⁰ Division of Nephrology, Rush University Medical Center, Chicago, Illinois.

PMID: 37341661
DOI: 10.1053/j.ajkd.2023.02.003

Abstract

The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases represents the first update to this set of recommendations since the initial set of KDIGO guideline recommendations was published in 2012. The pace of growth in our molecular understanding of glomerular disease has quickened and a number of newer immunosuppressive and targeted therapies have been introduced since the original set of guideline recommendations, making such an update necessary. Despite these updates, many areas of controversy remain. In addition, further updates since the publication of KDIGO 2021 have occurred which this guideline does not encompass. With this commentary, the KDOQI work group has generated a chapter-by-chapter companion opinion article that provides commentary specific to the implementation of the KDIGO 2021 guideline in the United States.

Keywords: CPG; Commentary; Glomerular disease; Glomerulonephritis; KDIGO 2021; KDOQI Work Group; Nephrotic syndrome.

Publication types

Practice Guideline

MeSH terms

Humans
Kidney Diseases* / diagnosis
Kidney Diseases* / therapy
United States